Search Press releases Keywords From To 18 Jan 2022 Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Non-Radiographic Axial Spondyloarthritis Study Read More 8 Jan 2022 Disposals of own shares Read More 3 Jan 2022 Disposals of own shares Read More 21 Dec 2021 Disposals of own shares Read More 16 Dec 2021 Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Ankylosing Spondylitis Trial Read More 10 Dec 2021 UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis Read More Pagination First page Previous page Previous … Page 26 Page 27 Page 28 Page 29 Current page 30 Page 31 Page 32 Page 33 Page 34 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
